Airtio instacaps are useful for asthma maintenance. They are prescribed to prevent and treat symptoms such as wheezing, shortness of breath and breathing difficulties associated with both asthma and COPD. It works by relaxing the muscles in the airways and widening them, thus making breathing easier.
Airtio is known to reduce inflammation and broncho constriction. It helps in decreasing Eosinophil and Neutrophil counts. This medicine is also notable for calming lung muscles and reducing exacerbations which occur due to an acute increase in the severity of a respiratory illness.
Airtio comes as a powder for inhalation (filled in capsules). For using Airtio Rotacaps you need to place the capsule at the base of the rota-haler. It is best to twist the mouthpiece completely and breathe in deeply through it. Hold your breath for up to 10 seconds and repeat the process.
Airtio is manufactured by Glenmark Pharmaceuticals Ltd headquartered in Mumbai. Glenmark is ranked among the world’s top 80 pharma and biotech companies. It was founded in 1977 and currently has 17 manufacturing facilities and 5 R&D centres dedicated to the goal of enriching lives across the globe.
You may have been prescribed Airtio Inhaler / Capsules if you are suffering from Asthma or COPD.
Asthma, also known as bronchial asthma is a condition in which the patient’s airways swell, narrow up and produce extra mucus. This can make breathing difficult and trigger coughing, wheezing and shortness of breath.
COPD, on the other hand is a lung disease chronic obstruction of lung airflow interferes with normal breathing. It is not a fully reversible disease.
Asthma triggers include air pollutants and irritants like smoke, dust mites, mould spores, pollen or pet dander. Cold air and respiratory infections like common cold can sometimes contribute to asthma. Excessive physical activity also known as exercise-induced asthma can also be one of the causes.
COPD can occur due to long-term exposure to irritating gases or particulate matter. It is often caused due to smoke from cigarettes. Additionally, patients suffering from COPD are at an increase risk of developing heart disease and lung cancer.
Often, Emphysema and chronic bronchitis lead to COPD. Chronic bronchitis is inflammation of the lining of the bronchial tubes, which carry air to and from the air sacs (alveoli) of the lungs. It is indicated by daily cough and mucus secretion.
Emphysema is a condition in which the alveoli at the end of the smallest air passages (bronchioles) of the lungs are destroyed as a result of damaging exposure to cigarette smoke and other irritating gases and particulate matter.
Patient w/ narrow-angle glaucoma, prostatic hyperplasia/bladder neck obstruction, cystic fibrosis. History of MI (<6 mth), or unstable or life threatening cardiac arrhythmia w/in the past yr. Not intended for use as initial treatment for acute bronchospasm and as monotherapy for asthma. Moderate to severe renal impairment (CrCl ≤50 mL/min). Pregnancy and lactation. Patient Counselling This drug may cause dizziness and blurred vision, if affected, do not drive or operate machinery. Monitoring Parameters Monitor pulmonary function.
Hypersensitivity to tiotropium bromide, atropine or its derivatives.
Additive effect w/ other anticholinergic drugs.
Inhalation: Inhalation cap: Store at 25°C. Protect from excessive heat and moisture. Do not store in inhaler device. Inhalation solution: Store at 25°C. Do not freeze.
Mechanism of Action
Tiotropium bromide antagonises the cholinergic effects of acetylcholine by reversibly and competitively binding to type 3 muscarinic (M3) receptors, resulting in bronchial smooth muscle relaxation.